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of IRP reforms as we found that even small changes to reference baskets used in 
IRP can lead to large negative financial impacts for pharmaceutical manufactures.
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Objectives: In most western countries it is a prerequisite before a new drug is 
approved into the reimbursement system that its cost-effectiveness has been dem-
onstrated. The pricing authorities’ assessment of the cost-effectiveness is usually 
based on a health economic evaluation required from the applicant. In Finland 
these evaluations have been obligatory since 1998. The objective of this study is to 
assess the present quality of these economic evaluations. MethOds: This study 
is based on a random sample of 13 economic evaluations submitted with price 
applications in Finland in 2012. These evaluations were assessed using a structured 
questionnaire with 25 different items. The items assessed include e.g. the choice 
of comparator, the method of analysis, the structure of the model, the estimation 
costs and health effects and the assessment of uncertainty. Results: Only two of 
the 13 evaluations were reliable enough for their results to be used as such in the 
pricing and reimbursement decision. In seven evaluations the results were of some 
use in the decision making. Among the reasons limiting their usefulness were that 
they contained uncertain assumptions, that some costs items were excluded from 
the analysis, and that the effectiveness of the treatments was based mainly on 
assumptions. Four economic evaluations could not be used in the decision making 
at all because the comparator was wrong, the effectiveness estimates were biased, 
or there was a lot of uncertainty attached to the key parameters (effectiveness, 
quality of life and costs). cOnclusiOns: There is still much to be improved in 
the quality of the submitted economic evaluations. This need for improvements is 
highlighted by the fact that the era of prolonged austerity has made it all the more 
important that only drugs with an acceptable cost-effectiveness ratio are accepted 
into the reimbursement system.
PHP92
dissecTing THe delAys: THe imPAcT Of new POlicies And PrAcTices On 
TOTAl Time TO reimbursemenT in OnTAriO
Mills F., Siu E., Poinas A.C., Wyatt G.
Wyatt Health Management, Oakville, ON, Canada
Objectives: To assess the effects of policy and institutional changes on the total 
Time to Reimbursement (tTTR) of innovative pharmaceutical products in Canada. 
Such changes include: the removal of criteria for “pre-NOC” drugs; queuing at CDR 
as its capacity to process submissions is stretched; and the emergence of the pan-
Canadian Pricing Alliance (pCPA), which negotiates with manufacturers on behalf 
of drug plans. MethOds: Using our proprietary CDR Tracker® database we assessed 
the tTTR, i.e. time from receipt of Notice of Compliance (NOC) to provincial reim-
bursement, for all CDR-reviewed drugs reimbursed by the Ontario Public Drug Plan. 
We separately examined the responsibilities of pharma manufacturers, CDR and 
the provinces themselves. We analyzed the Time to Submission, (TTS), i.e. NOC date 
to CDR submission date, Time to Recommendation (TTRec), i.e. CDR submission 
date to CDR recommendation date, and the Time to Decision (TTD) by the drug 
plan, i.e. recommendation date to Ontario formulary decision date. We assessed 
the tTTR for each year of CDR’s existence to identify changes of importance to 
manufacturers. Results: Removal of criteria for pre-NOC submissions increased 
their number: 17 pre-NOC submissions have occurred in months since the policy 
change, compared to 4 in total previously. Average TTS fell from 217 days to 151 days 
for drugs submitted before and after the change. TTRec prior to the queuing period 
was 203 ± 40 days. Since queuing was introduced this has increased to 214 ± 18 days. 
TTD has steadily declined over time and sharply since the arrival of pCPA. tTTR 
rose steadily from the beginning of CDR and fell sharply with the introduction of 
pCPA. cOnclusiOns: pCPA and CDR’s efforts have attentuated the consequences 
of queuing so far, though the full effect of the large and growing number of drugs 
currently in queue at CDR remains to be seen.
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Objectives: Numerous studies have examined prescription utilization and medi-
cation adherence using continuous enrollment criteria with claims data. Benefit 
design changes may have an impact on both measures. The purpose of this analysis 
was to indentify the multiple changes of benefit plan designs that occurred in a 
commercially insured population continuously enrolled for 30 months. MethOds: 
Retrospective study examining eligibility data and health plan benefit design 
records. Commercially insured beneficiaries aged 18 or older and enrolled from 
January 1st, 2011 through June 30th, 2013 were included. The benefit designs for 
all beneficiaries were identified from administrative records. Results: 2,489,106 
beneficiaries met enrollment criteria. Approximately 12% (289,159 beneficiaries) 
experienced at least one change in retail, mail, or Extended Supply Network (ESN) 
benefit design at some point during their enrollment. 248,734 beneficiaries (86.0%) 
experienced changes in retail benefit design; 261,526 beneficiaries (90.4%) expe-
rienced changes in mail benefit design; 97,548 beneficiaries (33.7%) experienced 
changes in ESN benefit design. Among the retail changes, 44,134 beneficiaries 
(17.7%) had a change in tier structure [23,490 with an increased in number of tiers; 
20,644 with a decreased in number of tiers]. Additionally, 10,627 beneficiaries (4.3%) 
with a retail tier copayment converted to a coinsurance design; 5,301 beneficiar-
ies (2.1%) with retail coinsurance converted to a tier copayment design; 173,760 
beneficiaries (69.9%) stayed in tier copayment design but had a change in retail 
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Objectives: To investigate the attitudes towards non-economic criteria to be 
used in resource allocation decisions in the health care sector among the Polish 
nurses. MethOds: A cross-sectional survey with pen and paper interview was 
designed. A responder was asked person trade-off question such as how many Y’s 
would be equivalent to 10 X’s. Characteristics of a hypothetical patient defined as 
X and Y varied in each of three decision making scenarios. Answers from a median 
responder were used for the estimation of disease severity and potential for health 
weights as well as aversion to inequalities in health. VAS scale was adopted. Cohen’s 
kappa coefficient and Fisher exact test were performed. Results: 100 nurses with 
on average of 15 years of professional experience were interviewed. In the first 
scenario, the utility gain was equal for both X and Y. The median responder chose 
10 and more Y to compensate for 10 X with a worse starting point. Half of partici-
pants valued health gain differently dependent on the baseline utility. In the second 
scenario, the median responder chose 10 Y to compensate for 10 X irrespective of 
X’s superior utility gain. Although X had a higher potential to benefit, only 32% of 
participants valued it more than Y. In the third scenario, the median responder 
required a greater number of subjects in program B to compensate for the lost of 
equality in the end health for both X and Y in program A. More than 65% of par-
ticipants valued health equality (program A) against greater health gain (program 
B). cOnclusiOns: Among study participants, an aversion to inequalities in end 
health was the most common. Different weightings of health gain dependent on 
the disease severity were accepted by half of participants. Majority of responders 
did not consider potential to benefit in their allocation decision.
PHP89
A QuAliTATive AnAlysis Of nice TecHnOlOgy APPrAisAls: idenTifying 
Trends And cOmmOnAliTies in resTricTed And nOn-recOmmended 
PHArmAceuTicAls
Cho Y.P, Dalsania R.R.
GfK Market Access, New York, NY, USA
Objectives: The number of technologies appraised by NICE has been increas-
ing since 2007, with a steep increase between 2009 and 2010. Much of this can be 
attributed to the influx of specialty pharmaceuticals, particularly targeted oncol-
ogy therapies. Along with this increase in the number of appraisals, the rate of 
‘restricted recommendations’ and ‘non-recommendations’ has also escalated. 
Various meanings and interpretations of ‘restricted’ can be applied depending on 
the area in which the restriction is applied (e.g. patient sub-groups, line of therapy). 
This research sets out to identify recurring trends and commonalities behind prod-
ucts that have received a ‘restricted recommendation’ or ‘non-recommendation’ 
as well as standardize the term ‘restricted’ based on the impact of the appraisal on 
market access. MethOds: NICE appraisals between January, 2001 and December, 
2013 was reviewed and analyzed through simple descriptive statistics. The content 
of the appraisals were closely reviewed to identify the criteria and key elements 
driving each decision. Results of this analysis were applied in standardizing the 
term ‘restricted’ in order to identify the implications of these restrictions on market 
access. Results: NICE appraised 176 technologies from January 2001 - December 
2013 (withdrawn appraisals and re-appraisal were not included in the analysis). 
Between the time periods of 2000-2007 and 2008-2013, the average number or 
appraisals a year nearly doubled. The rate of ‘restricted recommendation’ increased 
from 12% to 36% in the same time period and the number of ‘non-recommendations’ 
increased from 10% to 23%. cOnclusiOns: Given the high cost and targeted regi-
men of specialty pharmaceuticals, (e.g. biologic oncology therapies), ability to dem-
onstrate cost-effectiveness in broad patient populations has become increasingly 
challenging, leading to higher rates of ‘restricted recommendations.’ Commonalities 
among technologies receiving ‘non-recommendations’ include use of unacceptable 
comparators, endpoints, and study durations.
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Objectives: The objective of this study was to develop a conceptual framework 
to estimate potential consequences of IRP reforms by estimating the impact if a 
European country was to include Turkey into the set of countries that it uses to 
establish the reference price. MethOds: Phase 1 consisted of obtaining evidence on 
the IRP countries using a literature review from 2011 to 2013 (WHO/HAI Systematic 
Review - May 2011) based on ECONLIT, MEDLINE and grey literature. Phase 2 con-
sisted of developing a conceptual framework and model database to summarize 
IRP designs, reference baskets, methods and updates. Model inputs for the product 
included prices, volume, and launch phase. Phase 3 consisted of building and testing 
the model from a manufacturer perspective with a variable time horizon up to 5 
years. Products from the epidermal growth factor receptor (EGFR) class were selected 
to estimate the potential effects of including Turkey into the reference basket used 
by EU countries to calculate reference rules. Results: Four peer-reviewed and a 
number of websites and white papers were identified discussing IRP related issues. 
A conceptual framework was designed considering 1) database of IRP country rules, 
2) product data, and 3) model input interface to conduct one-way sensitivity analysis 
of a simulated IRP reform. Inclusion of Turkey into the reference basket of various EU 
markets lead to large negative financial impacts for companies with EGFR products. 
The countries that lead to the largest impact were Romania and Greece. The second 
order effects such as countries that re-referenced Greece and Romania were larger 
over the 5-year time frame compared with the primary effects. cOnclusiOns: 
The proposed conceptual framework may offer another tool to estimate the impact 
